Competing interests
S.J.S. was supported by research grants from the National Institutes of Health (U54 HL160273, R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), AstraZeneca, Corvia, and Pfizer; and has received consulting fees from Abbott, Alleviant, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol Myers Squibb, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Imara, Impulse Dynamics, Intellia, Ionis, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, ReCor, Regeneron, Rivus, Sardocor, Shifamed, Tenax, Tenaya, and Ultromics. L.H.L. was supported by Karolinska Institutet, the Swedish Research Council (grant 523-2014-2336), the Swedish Heart Lung Foundation (grants 20190310, 20220540), and the Stockholm County Council (grants 20190525 and FoUI-974688). L.H.L. has received to author’s institution: grants, consulting, honoraria: Alleviant, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Edwards, Merck/MSD, Novartis, Novo Nordisk, Owkin, Pharmacosmos; Stock ownership: AnaCardio. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from NovoNordisk and Roche Diagnostics; has served as consultant or on the advisory board/steering committee/executive committee for Alnylam Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, BridgeBio, Corteria, Corveus Medical, CPC Clinical Research, Cytokinetics, Daiichi Sankyo, Eli Lilly, EvlaBio, ICON Clinical Research, Impulse Dynamics, Intellia Therapeutics, Janssen Research & Development LLC, Klyv Therapeutics, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Pfizer, Radcliffe Group, Ribocure, Roche, Tenax and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. L.K. reports speaker honorarium from AstraZeneca, Boehringer, Novartis and Novo Nordisk. A.C.S. received consulting fees from Sanofi, Bayer, Merck, Boehringer Ingelheim, Novartis, AstraZeneca. SSvW has received consulting/speaker fees from AstraZeneca, Boehringer-Ingelheim, Novartis, Pfizer, and Roche Diagnostics and research support from AZ, BI, Pfizer and Roche diagnostics. J.F.K.S. reports speaker honorarium from Mantecorp, AstraZeneca, Lilly, Bayer, Boehringer-Ingelheim, Novartis, Novo Nordisk, and consulting fees from AstraZeneca and Novo Nordisk. P.E.P., E.M., A.M., H.E., M.A., A.C., M.T., C.W., N.B., A.L.V. and R.J.G.H. are employees of AstraZeneca. The remaining authors declare no competing interests.
